How it works:
Raltegravir inhibits HIV integrase, an essential enzyme required for the integration of viral DNA into the host genome. By preventing this step, the drug disrupts viral replication and limits the spread of the virus within the body.
Recommended for:
Adults and adolescents with confirmed HIV-1 infection
Patients undergoing antiretroviral therapy (ART)
Individuals with resistance to other classes of HIV medications
Treatment-naive patients beginning ART
Treatment of HIV-1 infection as part of combination antiretroviral therapy
Taken orally, usually 400 mg twice daily, with or without food. The dosage and duration of treatment are determined individually by the physician based on ART regimen and patient status.
Contraindications:
Hypersensitivity to raltegravir
Severe hepatic impairment
Children under 12 years old (for the 400 mg formulation)
Concurrent use with strong enzyme inducers (e.g., rifampin without dose adjustment)
Side effects:
Headache
Insomnia
Rash and itching
Elevated liver enzymes
Gastrointestinal disturbances (nausea, diarrhoea)
Fatigue
